

**KIT N. SIMPSON DrPH**  
**Department of Healthcare Leadership and Management**  
**College of Health Professions**  
**Medical University of South Carolina**

**151B Rutledge Ave, Room 412**  
**P.O. Box 250807**  
**Charleston S.C. 29425**

**Phone (843) 792-0760, FAX (843) 792-3327**  
**Email: simpsonk@musc.edu**

**EDUCATION**

Johns Hopkins University, School of Hygiene and Public Health, 1991 Robert Wood Johnson Faculty Fellow; Health Care Finance (Economic Evaluation and Outcomes Research)

University of North Carolina at Chapel Hill, School of Public Health, 1988, Dr.P.H.; Health Policy and Administration (Health Services Research)

University of North Carolina at Chapel Hill, School of Public Health, 1983, MPH; Health Policy and Administration (Financial Management)

Hospitalslaborantskolen, Copenhagen and Slagelse Centralsygehus (Central Hospital), Denmark 1965-68. Diploma Medical Technology

**PROFESSIONAL ACTIVITIES**

- 2005-present** Professor, DHA and MSHI Divisions, Healthcare Leadership and Management, College of Health Professions; Professor of Public Health Sciences, College of Medicine. Director, MUSC Comparative Effectiveness Data Analytics Resource (CEDAR) Core, Medical University of South Carolina, Charleston, S.C.
- 2004-2005** Interim Associate Dean for Research and Professor of Health Administration & Policy, College of Health Professions; Professor of Pharmacy and Clinical Sciences, College of Pharmacy; Professor of Biostatistics, Bioinformatics, and Epidemiology, College of Medicine; Investigator, Center for Health Economics and Policy Studies. Medical University of South Carolina, Charleston, S.C.
- 2000-2004** Professor and Vice Chair for Research, Department of Pharmacy Practice, College of Pharmacy; Professor of Biometry & Epidemiology, College of Medicine; Professor of Health Administration & Policy, College of Health Professions; Senior Investigator, Center for Health Economics and Policy Studies. Medical University of South Carolina, Charleston, S.C.
- 1998-2000** Professor, Faculties of Pharmacy and Health Administration & Policy, and Investigator, Center for Health Care Research, Medical University of South Carolina, Charleston, S.C.
- 1985-98** Associate Professor (with tenure), and Assistant Professor 1985-95, and Director Executive MPH Program, Department of Health Policy and Administration, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC (on leave 1996/98).
- 1997-98** Director, Health Economics Research, Chiron Corporation, Emeryville CA, and Director of Clinical Epidemiology/Economics, Chiron Informatics, Alameda CA.
- 1996-97** Associate Professor of Pharmacoeconomics, Center for Health & Social Policy, School of Business and Economics, University of Odense, Denmark.
- 1991-97** Visiting Research Scientist for Economic Modeling Studies, Battelle MEDTAP and MEDTAP International, Arlington, VA.

- 1985-89** Director of Executive Master's Programs (Clinical Assistant Professor). Health Policy and Adm., School of Public Health, UNC.
- 1980-85** Director of Allied and Public Health Education, Mountain Area Health Education Center (AHEC), Asheville, NC and Adjunct Assistant Professor, UNC School of Medicine.
- 1978-80** Program-Coordinator, The Health Adventure, Asheville, NC.
- 1979** Instructor. Medical Practice Management Curriculum. Cecil's Jr. College, Asheville NC.
- 1976-78** Practice Manager, G.A. Simpson, M.D., and Associates, Asheville, NC. Occupational Medicine.
- 1972** Clinical Services Manager, Herbert Simpkins, M.D., Irvington, N.J.
- 1969-71** Chief Research Technologist, Division of Nephrology, Cornell Medical College, N.Y.
- 1968** Laboratory Supervisor, Central Laboratory and Blood Banking, Lasarettet Hospital, Gaellivare, Sweden.
- 1968** Staff Medical Technologist, Slagelse Central Sygehus, Slagelse, Denmark.

**Honors:**

2018 Advancement of Women Award. Women Scholar Initiative, MUSC.  
 Scholar of the Year. MUSC College of Health Professions 2007 and 2014.  
 Collaborating Faculty Scholar Award, MUSC Physician Assistant Program August 2006.  
 Health Care Management Research Award. American College of Healthcare Executives, 1991  
 The Robert Wood Johnson Foundation Faculty Fellowship in Health Finance, 1991-93  
 Distinguished Scholar in Allied Health, Albany State College, Albany, Georgia, 1985  
 Public Health Service Traineeship, 1984-1986  
 Delta Omega Graduate Public Health Honor Society, 1983

**Boards and Committees:**

Member of the Editorial Board for the peer-reviewed journal: Clinical Medicine & Research 2007

NIAID, National Institute of Health. Member, Special Emphasis Grant Review Panel: AIDS Clinical Research Network. 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014

American Cancer Society Pilot Study Grant Proposal Reviewer. Hollings Cancer Center. 2005, 2006, 2007, 2009

NCI P01 Program. Special emphasis panel grant reviewer: 2006, 2007, 2008, 2010, 2011

Netherlands Board of Health Research and Development; proposal reviewer for prevention proposals 2008.

Member MUSC IRB, January 2007- December 2009; reappointed for 2010.

Member, MUSC Advisory Committee for NIH T32 Pre-doctoral Training Roadmap grant. 2006-present

Co-Chair for Study Design and Statistical Methods workgroup for the MUSC Clinical and Translational Science Award.

Member MUSC T20 Translational Research Fellowship Advisory Group. 2007- present.

Member, CHP Research Council. 2006- present.

Planning Consortium Member, 1999-2000 for the Tri-national Trial of Options in Management with Antiretrovirals (OPTIMA), and Member Health Economics Core for the UK component of OPTIMA. 2000-2005.

Expert Panel. Traumatic Brain Injury Rehabilitation, NIH Consensus Conference. August 1997 to October 1998.

HIV/AIDS Economics Review Group. Cochran Collaboration, San Francisco 1998.

MPH Degree Development Commission. Universities of Copenhagen, Aarhus and Odense, Denmark 1996-97.

Scientific Committee. First European Conference on the Economics of Cancer. European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium. 1997.

Scientific Committee. Second European Conference on the Economics of Cancer. EORTC, Brussels, Belgium. 2000.

AIDS Economics Research Collaboration, London, United Kingdom 1996-2000.

Information Systems Development and Research Committee, Kobler Center, Chelsea and Westminster Hospital, London England. 1995-98.

UNC School of Public Health, Department of Health Policy and Administration: Doctoral Program Advisory Committee 1988-98; Academic Standards/Curriculum Committee, 1988-91; Strategic Directions Committee, 1985-86; Executive Committee 1986-88; Committee for Development of Award for Excellence in Health Administration 1984, 1986; Advisory Committee on Non-Residential Programs, 1984

UNC School of Public Health Institutional Review Board, 1995-1997.

Committee to review Dean Michel Ibrahim for re-appointment, 1991.

UNC Faculty Council member 1990-93

Theta Chapter, Delta Omega Graduate Public Health Honor Society. President 1993-94. Treasurer 1989-91, Secretary 1991/92, Vice President 1992-93

Advisory Committee on Primary Care Institutes, National Association of Community Health Centers 1993

American Public Health Association, Chair of Health Administration Section 1991-93; Chair of Quality Management Committee; Governing Council Member 1987-89; Section Council Member, 1983, 1984-87; Policy Development Committee 1986, 1987, 1988, 1989, 1990; Chair of Scientific Program Committee, 1986; member 1983, 1984, 1987;

North Carolina Hospital Association, DRG Education Committee, 1983

**Reviewer for the following journals:** JAMA; AIDS; JAIDS; AIDS Care; AIDS Research and Therapy; Health Economics; PharmacoEconomics; Value in Health; Disease Management & Health Outcomes; Medical Care; CRMO; American J. of Public Health; Hospital & Health Services Administration; J. of Health Services Research; J of Preventive Medicine; J. of Urology; National Journal of Medicine; J of Rheumatology; J Obstetrics & Gynecology; PLOS One, Stroke, Medical Economics.

**TEACHING** (includes only courses taught in last 4 years)

### **Master of Science in Health Informatics**

#### HIN 708 Applied Statistical and Research Methods

This course provides a working knowledge of the most common approaches used to describe and visualize population characteristics, and standard statistical tests used to identify associations between variables. We will use archival data from patient medical encounters (hospital admissions and medical office visits) to: 1) define a patient cohort using ICD-9 and/or CPT codes to define a phenotype; 2) describe the characteristics of the patient population; 3) identify associations between patient characteristics and medical encounter measures; 4) report the findings using tables and graphics; and 5) discuss the findings. Examples of reports from the medical literature will be used to examine how the study design, data source, and variable measurement affect the ability to draw conclusions about cause and effect versus association.

### **Doctor of Health Administration**

### DHA 867 Quantitative Methods for Research

This course is designed to give students the skills to use data sets and conduct quantitative analysis to address research questions. The course will use actual public-use secondary data sets to provide students experience with data management. The course will also provide presentation of statistical principles and methods most commonly used in health services research. Finally, the course will prepare students in the use of SPSS statistical analysis software.

### DHA 870 Advanced Techniques in Applied Research

Advanced seminar on principles and techniques for designing and implementing health care and managerial research studies. Students will learn to critically assess the literature and develop a dissertation proposal concept summary based on a topic of interest to them.

### DHA 875 Comparative Effectiveness Research

This course is the rigorous evaluation of the impact of different options that are available for treating a given medical condition for a particular set of patients. Topics include, 1) a review of research designs and statistics methods for comparative effectiveness research, 2) measurement of efficacy, effectiveness, cost and quality of life, 3) benchmarks for economic value, cost effectiveness, cost utility, and budget impact, 4) mathematical approaches for estimating expected outcomes; decision trees and Markov models. Use of current literature will be required as a means to examine examples of good and bad study design.

DHA 890 Doctoral Project. 27 credit hour Doctoral project required for graduation.

## **Doctor in Health and Rehabilitation Science**

HRS-820. Statistical Methods for Rehabilitation Science. This course provides a working knowledge of approaches to the analysis of archival data in rehabilitation research. Topics include 1) data set and variable description; 2) issues of ascertainment bias associated with retrospective data; 3) criteria for the selection of descriptive statistics; 4) visual presentation of parameters; 4) formulation of hypotheses appropriate for the data; 5) multivariable analysis for continuous dependent variables; 6) log transformation; 7) logistic regression; 8) Kaplan Meier curves; 9) controls for selection bias; 10) use of factor and cluster analysis for data reduction; 11) interpretation of outputs from SAS and SPSS statistical software; 12) presentation and discussion of results. Students will use SAS or SPSS software to perform analyses of observational data to answer rehabilitation questions and interpret results in terms of both clinical and statistical conclusions.

HRS-812. Seminar in Health Services Research. A health services research covering the evolution of HSR over the last 40 years. Students will review the original studies that effected the major 'paradigm shifts' that HSR has undergone since the 1970s. Students will discuss classical health services models and design approaches and critically analyze contemporary HSR studies, in view of the models, designs, and methods used in the classical studies.

HRS-990. Doctoral Dissertation. Dissertation work includes original investigation that gives evidence of mature scholarship and critical judgment, indicates knowledge of research methods and techniques, and demonstrates the ability to carry out independent investigation.

## **REFEREED PUBLICATIONS**

- 171 Dellito A, Friedman M, Albert M, Patterson C, Stevans J, Brennan G, Wegener S, Morrissette D, Benecuiuk J, Freel J, Minick K, Lake S, Lemaster C, Daley K, Tamasy M, Mishuris RG, Plumb D, Freburger J, Jeong J, Greco C, Kojha S, Epraim P, Williams C, Schneider M, Sowa G, Cash J, Wasan A, Adams W, Simpson KN, George S, Saper R, Hunter S, Spigle W, Hough L. Study Protocol for Targeted Interventions to Prevent Chronic Low Back Pain (TARGET Trial). *Contemporary Clinical Trials* under review
- 170 Amallouhi A, Holmstedt CA, Alkasab S, Harvey J, Simpson KN, Debenham E, Turnet NL. Teleneurology network to improve access to neurologists for patients in rural areas: A real-world experience. *Telemedicine & Health* forthcoming.
- 169 Tipton T, Edwards K, Simpson KN et al. Pathologic specimens at time of pyeloplasty: Frequency and practice patterns. *Urology* 2018 122(8):158-161.
- 168 Belanger KJ, **Simpson KN**, Armitage J, Carden RE. The effect on blood supply when implementing donor interval strategies to prevent iron deficiency. *Medical Laboratory Observer* 2018 50(10):12-16.
- 167 Karp EL, Freedman R, **Simpson KN**, Simpson AN. Changes in Efficiency and Quality of Nursing EHR Documentation after Implementation of an Admission Patient History Essential Dataset. *Computers, Informatics, Nursing* forthcoming.
- 166 **Simpson KN**, Seamon BA, Hand BN, Roldan CO, Taber DJ, Moran WP, Simpson AN. Effect of frailty on resource use and cost for Medicare patients. *J Comp Eff Res* 2018 doi:10.2217/ce-2018-0029.
- 165 Andrews AL, Brinton D, **Simpson KN**, Simpson AN (2018). A longitudinal Examination of the Asthma Medication Ratio in Children. *American Journal of Managed Care* (In Press).
- 164 Simpson KN, Simpson AN, Maulden P, Palesch Y, et al. Observed Cost and Variations in Short Term Cost-effectiveness of Therapy for Ischemic Stroke in IMS III. *JAHA J Am Heart Assoc.* 2017 May 8;6(5). pii: e004513. doi: 10.1161/JAHA.116.004513.
- 163 Wilmskoetter J, Simpson AN, Logan S, **Simpson KN**, Bonilha HS (2017). Impact of gastrostomy feeding tube placement on the one-year trajectory of care in working age, privately insured patients after stroke. *Nutrition in Clinical Practice.* doi:10.1002/ncp.10015.
- 162 Simpson AN, Wilmskoetter J, Hong I, Li CY, Jauch EC, Bonilha HS, Anderson K, Harvey J, **Simpson KN**. (2017). Stroke Administrative Severity Index (SASI): Using administrative data for 30-day post-stroke outcomes prediction. *Journal of Comparative Effectiveness Research* 2017 Oct 23. doi:10.2217/ce-2017-0058.
- 161 Li CY, Romero S, **Simpson AN**, Bonilha HS, Simpson KN, Hong I, & Velozo CA. (2017). Functional Independence Measure - Minimum Data Set Motor Item Bank: Short Forms Development and Precision Comparison in Veterans. *Arch Phys Med Rehabil.* 2017 doi: 10.1016/j.apmr.2017.06.022.
- 160 Harvey J, Valenta SR, **Simpson KN**, Lyles MA, McElligott JT. Utilization of Outpatient Telehealth Services in Parity and Non-Parity States 2010-2015. *Telemed eHealth* in process.
- 159 Simpson AN, **Simpson KN**, Dubno JR. Healthcare costs are substantially higher in insured older US adults with hearing loss. *JAGS* 2018.
- 158 Davis M, O'Connell T, Johnson S, Cline S, **Simpson KN**. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia. *Curr Alzheimer Res* 2018 Jan 18. doi: 10.2174/1567205015666180119092427.

- 157 Simpson AN, Wilmskoetter J, Hong I, Li CY, Jauch EC, Anderson K, Bonilha HS, Harvey J, **Simpson KN**. Stroke Administrative Severity Index: Using administrative data for 30-day post stroke outcomes prediction. *J Comp Eff Res* 2017 6(6) doi 10.2217/cer-2017-005 Epub 2017 Oct 23.
- 156 Tennessee AM, Bradham TS, White BM, **Simpson KN**. The Monetary Cost of Sexual Assault to Privately Insured US Women in 2013. *Am J Public Health*. 2017 Jun;107(6):983-988. doi: 10.2105/AJPH.2017.303742. Epub 2017 Apr 20.
- 155 Wilmskoetter J; **Simpson KN**; Bonilha HS. Hospital Readmissions of Stroke Patients with Percutaneous Endoscopic Gastrostomy Feeding Tubes. *J Stroke & Cerebrovas Dis*. 25(10):2535-42, 2016
- 154 Wilmskoetter J; Simpson AN; **Simpson KN**; Bonilha HS. Practice Patterns of Percutaneous Endoscopic Gastrostomy Tube Placement in Acute Stroke: Are the Guidelines Achievable? *J Stroke & Cerebrovas Dis*. 25(11):2694-2700, 2016.
- 153 Goodwin AJ, Nadig NR, McElligott JT, et al. Where You Live Matters: The Impact of Place of Residence on Severe Sepsis Incidence and Mortality. *Chest* 2016 150(4):829-836.
- 152 Andrews AL, Bundy DG, **Simpson KN**, Teufel RJ, Harvey J, Simpson AN. Inhaled Corticosteroid Claims and Outpatient Visits After Hospitalization for Asthma Among Commercially Insured Children. *Academic Pediatrics*, 2017 17(2):212-217..
- 151 Nadig N, Goodwin A, Simpson AN, Richards JE, **Simpson KN**, Ford D. Patient and Hospital Characteristics Associated with Inter-hospital Transfer for Adults with Ventilator Dependent Respiratory Failure. *Ann Am ThoraSoc* 2017 14(5):730-736.
- 150 Basco WT, Garner SS, Ebeling M, Hulsey TC, **Simpson K**. Potential Acetaminophen and Opioid Overdoses in Young Children Prescribed Combination Acetaminophen/Opioid Preparations. *Pediatric Quality and Safety* 2016 Dec 1; 2(1), doi: 10.1097/pq9.000000000000007.
- 149 Mims LD, Porter M, **Simpson KN**, Carek P. The “July Effect”: A Look at Medical Admissions. *J Am Board Fam Med* 2016 30(2):189-195.
- 148 Scahill CJ, **Simpson KN**. Thrombosis Following Pediatric Cardiac Surgery is Associated with Significant Morbidity, Mortality and Cost. *Pediatric Critical Care Medicine* in process.
- 147 White BM, Horton LS, **Simpson KN**. Community-level characteristics of high infant mortality: A tool to identify at-risk . *J Health Disparities Research and Practice* 2017.
- 146 Johnson EE, Simpson AN, Harvey JB, Lockett MA, Byrne KT & **Simpson KN**. (2016). Trends in bariatric surgery, 2002-2012: do changes parallel the obesity trend?. *Surgery for Obesity & Related Diseases*, 12, 398-404. doi:10.1016/j.soard.2015.07.009
- 145 Johnson EE, Simpson AN, Harvey JB , **Simpson KN**. (2016). Bariatric surgery implementation trends in the USA from 2002 to 2012. *Implementation Science*, 11, 21. doi:10.1186/s13012-016-0382-x
- 144 Marlow NM, Kazley AS, Chavin KD, **Simpson KN**, Balliet W & Baliga PK. (2016). A patient navigator and education program for increasing potential living donors: a comparative observational study. *Clinical Transplantation*, 30, 619-27. doi:10.1111/ctr.12728
- 143 Marlow NM, **Simpson KN**, Kazley AS, Balliet WE, Chavin KD & Baliga PK. (2016). Variations in coping stages for individuals with chronic kidney disease: Results from an exploratory study with patient navigators. *Journal of Health Psychology*, 21, 1299-310. doi:10.1177/1359105314551776
- 142 White BM, Jones WJ, Moran WP & **Simpson KN**. (2016). Effect of the Economic Recession on Primary Care Access for the Homeless. *Journal of Health Care for the Poor & Underserved*, 27, 1577-91. doi:10.1353/hpu.2016.0104
- 141 Simpson AN, **Simpson KN**, Dubno RJ. Higher health care costs in middle-aged US adults with hearing loss. *JAMA Otolaryngol Head Neck Surg* 2016 doi:10.1001/jamaoto.2016.0188. PMID: 27054903.

- 140 Basco WT, Garner SG, Ebeling M, Freeland KD, Hulsey TC, Simpson KN. Evaluating the Potential Severity of Look-Alike, Sound-Alike Drug Substitution Errors in Children. *Academic pediatrics* 2016;16:183–191
- 139 Simpson AN; Bonilha HS; Kazley AS; Zoller JS; **Simpson KN**; Ellis C. Impact of Outpatient Rehabilitation Medicare Reimbursement Caps on Utilization and Cost of Rehabilitation Care After Ischemic Stroke: Do Caps Contain Costs? *Archives of Physical Medicine & Rehabilitation*. 96(11):1959-65.e4, 2015 Nov.
- 138 Ford DW, Goodwin AJ, Simpson AN, Johnson EJ, Nadig N, **Simpson KN**. A severe sepsis prediction model and score to use with administrative data. *Crit Care Med* 2016; 44:319–327
- 137 Kazley AS, Hund JJ, **Simpson KN**, Chavin K, Baliga P. Health literacy and kidney transplant outcomes. *Progress in Transplantation*. 25(1):85-90, 2015 Mar.
- 136 Sistino JJ, Atz AM, Ellis C Jr, **Simpson KN**, Ikonomidis JS, Bradley SM. Association Between Method of Cerebral Protection During Neonatal Aortic Arch Surgery and Attention Deficit/Hyperactivity Disorder. *Annals of Thoracic Surgery*. 100(2):663-70, 2015 Aug.
- 135 Broderick JP; Berkhemer OA; Palesch YY; Dippel DW; Foster LD; Roos YB; van der Lugt A; Tomsick TA; Majoie CB; van Zwam WH; Demchuk AM; van Oostenbrugge RJ; Khatri P; Lingsma HF; Hill MD; Roozenbeek B; Jauch EC; Jovin TG; Yan B; von Kummer R; Molina CA; Goyal M; Schonewille WJ; Mazighi M; Engelter ST; Anderson CS; Spilker J; Carrozzella J; Ryckborst KJ; Janis LS; **Simpson KN**; IMS II; MR CLEAN Investigators. Stroke. 46(12):3416-22, 2015 Dec. Endovascular Therapy is Effective and Safe for Severe Ischemic Stroke: Pooled Analysis of IMS III and MR CLEAN. *Stroke* 2015 46(12):3416-22. doi: 10.1161/STROKEAHA.115.011397.
- 134 Stanowski AC, **Simpson K**, White A. Pay for Performance: Are Hospitals Becoming More Efficient in Improving Their Patient Experience? *J Healthc Manag*. 60(4):268-85, 2015.
- 133 Kazley,AS; Hund JJ, **Simpson KN**, Chavin K, Baliga. Health literacy and kidney transplant outcomes. *Prog Transplant*. 25(1):85-90, 2015.
- 132 Palesch YY, Yeatts SD, Tomsick TA, Foster LD, Demchuk AM, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, von Kummer R, Molina CA, Goyal M, Schonewille WJ, Mazigh M, Engelter ST, Anderson C, Spilker J, Carrozzella J, Ryckborst KJ, Janis LS, Simpson AN, **Simpson KN**, and Broderick JP, for the Interventional Management of Stroke III Investigators. Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial. *Stroke* 2015;46:1321-1327. doi:10.1161/STROKEAHA.115.009180.
- 131 Goodwin AJ, Rice DA, **Simpson KN**, Ford DW. Frequency, cost, and risk factors of readmission among severe sepsis survivors. *Crit Care Med* 2015; 43:738–746.
- 130 Sistino, J. J., Atz, A. M., **Simpson, K. N.**, Ellis, C., Ikonomidis, J. S., & Bradley, S. M. (2014). The prevalence of attention-deficit/hyperactivity disorder following neonatal aortic arch repair. *Cardiol Young*, 1-7. doi: 10.1017/S1047951114000547
- 129 **Simpson K N**, Chen SY, Wu A W, Boulanger L, Chambers R, Nedrow K, Tawadrous M, Pashos C L, Haider S. Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors. *HIV Medicine* 2014 15(8):488-98.
- 128 Simpson AN, **Simpson KN**, Dubno JR. Health-related quality of life in older adults: Effect of hearing loss and common chronic conditions. *Healthy Aging Research* 2015 4:4.
- 127 Kazley AS, Jordan J, **Simpson KN**, Chavin K, Rodrigue J, Baliga P. Development and testing of a disease-specific health literacy measure in kidney transplant patients. *Prog Transplant* 2014 24(3):263-70.
- 126 White BM, Ellis Jr C, **Simpson KN**. Preventable hospital admissions among the homeless in California: A retrospective analysis of care for ambulatory care sensitive conditions. *BMC Health Serv Res*. 2014 Oct 25;14(1):511. [Epub ahead of print] PMID: 25344441.
- 125 Johnson EE, **Simpson KN**. Discharge disposition after bariatric surgery. *Obes Surg*. 2014 Oct;24(10):1821-5. doi: 10.1007/s11695-014-1372-1. PMID:25056234.

- 124 Wang L, Haider S, Nedrow K, Chambers R, Tawadrous M, Baser O, **Simpson KN**. HIV economic burden of illness in the Veterans Health Administration population. *AIDS Care*. 2015 Jan;27(1):123-31. doi: 10.1080/09540121.2014.947237. Epub 2014 Sep 16. PMID:25225150
- 123 **Simpson KN**, Simpson AC, Mauldin PD, Hill MD, Yeatts SD, Spilker JA, Foster LD, Khatri P, Martin RL, Jauch EC, Kleindorfer D, Palesch YY, Broderick JP, for the IMS III Investigators. Drivers of Costs Associated with Reperfusion Therapy in Acute Stroke: The IMS III Trial. *Stroke* 2014 45(6):1791–1798 DOI: 10.1161/STROKEAHA.113.003874.
- 122 Solem CT, Snedecor SJ, Khachatryan A, Nedrow K, Tawadrous M, Chambers R, Haider S, **Simpson KN**. Cost of Treatment in a US Commercially Insured, HIV-1-Infected Population. *PLOS One* 2014 May 27, 2014 DOI: 10.1371/journal.pone.0098152.
- 121 **Simpson K**, Chen SY, Wu A, Boulanger L, Chambers R, Nedrow K, Tawadrous M, Pashos C, Haider S. Cost of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors. *HIV Med*. 2014 Mar 18. doi: 10.1111/hiv.12145. PMID: 24641448
- 120 Sanders RB, **Simpson KN**, Kazley AS, Giarrizzi DP. New hospital telemedicine services: Potential market for anighttime telehospitalist service. *Telemed J E Health*. 2014 Mar 24. PMID: 24660844
- 119 Savage AH, Marlow NM, Alkis MH, **Simpson KN**. Cost effectiveness analysis for two surveillance options for cervical intraepithelial neoplasia 1. *J Tract Low Genit Dis*. 2014 Apr;18(2):136-41. doi: 10.1097/LGT.0b013e31829eaf31. PMID: 24270194
- 118 Zapka J, **Simpson K**, Hiot L, Langston H, Fakhry S, Ford D. A mixed method investigation of readiness to change in rural hospitals participating in a tele-critical care intervention. *BMC Health Services Research* 2013, 13:33
- 117 Hawk AF, Chang EY, Shields SM, **Simpson KN**. Cost and clinical outcomes of non-invasive RhD typing for target prophylaxis. *Obstetrics & Gynecology*. 122(3):579-85, 2013 Sep.
- 116 Desai K, Moller J, **Simpson K**, Baran R, Vandesteen O, Dietz B, Gooch K. Cost-minimization of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age. *J Med Econ* 17(4):250-8. doi: 10.3111/13696998.2013.877469.
- 115 **Simpson KN**, Hanson KA, Harding G, Haider S, Tawadrous M, Khachatryan A, Pashos CL, Wu AW. Review of the impact of NNRTI-based HIV treatment regimens on patient-reported disease burden. *AIDS Care*. 26(4):466-75, 2014 Apr.
- 114 **Simpson KN**, Hanson KA, Harding G, Haider S, Tawadrous M, Khachatryan A, Pashos CL, Wu AW. Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review. *Health and Quality of Life Outcomes* 2013 11:164:1-15.
- 113 Kazley AS, **Simpson KN**, Simpson AN, Jauch EC, Vick J, Adams RJ. Optimizing Economic Impact of rt-PA Use in a Stroke Belt State: The Case of South Carolina. *Am Health & Drug Benefits*. 2013.
- 112 Bushardt RL, Taylor LA, Rader AM, **Simpson KN**, McCart MR, Hildebrandt CA, Furberg C. The Influence of Urbanization on Blood Pressure and Obesity in Ambulatory Care Patients in Togo, West Africa. *Ethnicity & Disease*. Forthcoming.
- 111 Wu AW, Hanson KA, Harding G, Tawadrous M, Khachatryan A, Pashos CL, **Simpson KN**. Responsiveness of the MOS-HIV and the EQ-5D in HIV-infected adults receiving antiretroviral therapies. *Health & Quality Life Outcomes* 2013 11(42):1-8.
- 110 **Simpson KN**, Pei PP, Möller J, Baran RW, Dietz B, Woodward W, Migliaccio-Walle K, Caro JJ. Lopinavir/ritonavir versus darunavir plus ritonavir for human immunodeficiency virus disease: A cost-effectiveness analysis for the United States. *PharmacEconomics* 2013 31:427-444.
- 109 **Simpson KN**, Marlow N, Shaw J, Rudakova AV. Фармакоэкономические аспекты терапии ингибиторами фактора некроза опухоли хронического увеита, рефрактерногок базисной терапии (в том



- числе ассоциированного с ювенильным идиопатическим артритом) [Pharmacoeconomic issues of adalimumab therapy in juvenile idiopathic arthritis in Russia] *Pharmacoeconomics in Pediatrics* 2012 8(4):55-58.
- 108 Kazley AS, **Simpson KN**, Chavin KD, Baliga P. Barriers facing patients referred for kidney transplant cause loss to follow-up. *Kidney Int.* 2012 Nov;82(9):1018-23. doi: 10.1038/ki.2012.255. Epub 2012 Jul 25.
- 107 Andrews AL, Lazenby GB, Unal ER, **Simpson KN**. The cost of Medicaid savings: the potential detrimental public health impact of neonatal circumcision defunding. *Infect Dis Obstet Gynecol.* 2012;2012:540295. doi: 10.1155/2012/540295. Epub 2012 Oct 18.
- 106 Andrews AL, Teufel RJ 2nd, Basco WT Jr, **Simpson KN**. A cost-effectiveness analysis of inhaled corticosteroid delivery for children with asthma in the emergency department. *Infect Dis Obstet Gynecol.* 2012;2012:540295. doi: 10.1155/2012/540295. Epub 2012 Oct 18.
- 105 **Simpson KN**, Baran RW, Collomb D, Beck EJ, Van de Steen O, Dietz B. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and –experienced United Kingdom patients in 2011. *J Medical Econ* 2012 15(4):796-806.
- 104 Post RE, Mainous AG 3<sup>rd</sup>, King DE, **Simpson KN**. Dietary fiber for the treatment of type 2 diabetes mellitus: a meta-analysis. *J Am Board Fam Med* 2012 25(1):16-23.
- 103 Hill MD, Khatri P, **Simpson KN**, Broderick JP. Letter by Hill et al Regarding Article, “A cost utility analysis of mechanical thrombectomy as an adjunct to intravenous tissue-type plasminogen activator for acute Large-vessel ischemic stroke”. *Stroke* 2011; 42:e641-e642.
- 102 **Simpson KN**, Tilley BC. Economic Analysis of Secondary Trial Data. *Progress in Cardiovascular Diseases*, 2012, 54(12):351-356.
- 101 Lazenby GB, Unal ER, Anne Lintzenich A, **Simpson KN**. A cost-effectiveness analysis of anal cancer screening in HIV-positive women. *J Lower Genital Tract Disease.* 2012 Jan 5[Epub ahead of print] PubMed PMID: 22227844.
- 100 Ellis C, Simpson AN, Bonilha HS, Mauldin PD, **Simpson KN**. The one-year attributable cost of post-stroke aphasia. *Stroke* 2012 May;43(5):1429-31.
- 99 **Simpson KN**, Baran R, Kirbach SE, Dietz B. Economics of Switching to Second-Line Antiretroviral Therapy with Lopinavir/ritonavir (LPV/r) in Africa: Estimates Based on DART Trial Results and Costs for Uganda and Kenya. *Value Health* 2011 14(8):1048-54.
- 98 Unal RE, Lazenby GB, Lintzenich AE, **Simpson KN**, Newman R, Goetzl L. Cost-Effectiveness of Maternal Treatment to Prevent Perinatal Hepatitis B. *Obst & Gyn.* 2011 118(3):655-62.
- 97 **Simpson KN**, Dietz B, Baran R, Bhor M., Garren KW, Riddler SA, Haubrich RH. Economic Modeling of the Combined Effects of HIV-Disease, Cholesterol and Lipoatrophy Based on ACTG 5142 Trial Data. *Cost Effectiveness and Resource Allocation.* 9:5 May 2011.
- 96 Hornberger J, **Simpson K**, Shewade A, Gietz B, Baran R, Podsadecki T. Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy. *Advances Ther* 2010 27(11):763-73.
- 95 Moreau NG, **Simpson KN**, Teefey SA, Damiano DL. Muscle architecture predicts maximum strength and is related to activity levels in cerebral palsy. *Phys Ther.* 2010 Nov; 90(11):1619-30.
- 94 Fine SH, Loeheide L Swanson-Kazley A, Clarke RL, **Simpson KN**. Assessing the benefits of teleintensivist coverage in the ICU. *Healthcare Fin Manag* 2010 64(12):84-8.
- 93 Moore BR, **Simpson K**, Kaye W, Swanson Kazley A. Piloting a method to measure satisfaction with HIV care. *Am J Med Quality* 2010 25(5):384-91.

- 92 Basco WT Jr, Ebeling M, Hulsey TC, **Simpson KN**. Using pharmacy data to screen for look-alike, sound-alike substitution errors in pediatric prescriptions. *Acad Pediatr* 2010 10(4):233-7.
- 91 **Simpson KN**. Economic Modeling of HIV Treatments. *Current Opinion in HIV and AIDS* 2010 5(3):242-8.
- 90 Worrall CL, Anger BP, **Simpson KN**, Leon SM. Impact of a hospital-acquired/ventilator-associated/healthcare-associated pneumonia practice guideline on outcomes in surgical trauma patients. *J Trauma* 2010 68(2):382-6.
- 89 Anderegg BA, Worrall C, Barbour E, **Simpson KN**, Delegge M. Comparison of resting energy expenditure prediction methods with measured resting energy expenditure in obese, hospitalized adults. *Journal of Parenteral & Enteral Nutrition*. 2009 33(2):168-75.
- 88 Robinson CJ, Villers MS, Johnson DD, **Simpson KN**. Timing of Elective Repeat Cesarean Delivery at Term and Neonatal Outcomes: A Cost Analysis. *American Journal of Obstetrics & Gynecology* 2010 202(6):632.
- 87 McKinzie B, Worrall C, Coulliard DJ, **Simpson KN**, Leon SM. Impact of Elevated Percent Carbohydrate-Deficient Transferrin at Hospital Admission on Outcomes in Trauma Patients. *The American Surgeon* 76(5):492-6.
- 86 Kazley AS, Hillman DG, **Simpson KN**, Johnston KC. Hospital care for stroke patients on the weekends versus weekdays: Is there a disparity in the quality and aggressiveness of care? *Arch Neurol* 2010 67(1):39-44.
- 85 Garin M, Highland K, **Simpson KN**, Chumney ECG, Clark L. Cost-utility of treatments for pulmonary hypertension. *Clin Drug Invest* 2009 29(10) 635-46
- 84 Williams N, Simpson AN, **Simpson KN**, Nahas Z. Relapse rates with long term antidepressant drug therapy: A meta-analysis. *Human Psychopharmacology* 2009 24(5) 401-8.
- 83 **Simpson KN**, Welch MJ, Kozel FA, Demitrack MA, Nahas Z. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health Economics analysis. *Adv Ther* 2009 26(3): 346-68.
- 82 **Simpson KN**, Rajagopalan R, Dietz B. Cost-effectiveness analysis of Lopinavir/Ritonavir and Atazanavir+Ritonavir regimens in the CASTLE study. *Adv Ther* 2009 26(2): 185-193.
- 81 Teufel RJ 2<sup>nd</sup>, Basco WT Jr, **Simpson KN**. Cost effectiveness of an inpatient influenza immunization assessment and delivery program for children with asthma. *J. Hosp. Medicine* 2008 3(2):134-41.
- 80 Hayslip JW, **Simpson KN**. Cost-Effectiveness of Extended Adjuvant Rituximab for US Patients Aged 65-70 Years with Follicular Lymphoma in Second Remission. *Clinical Lymphoma & Myeloma*. 8(3) 2008.
- 79 **Simpson KN**, Roberts G, Hicks CB, Finnern HW. Cost-effectiveness of Tipranavir in Treatment Experienced HIV Patients in the US. *HIV Clinical Trials* 2008 9(4):225-37.
- 78 **Simpson KN**, Strassburger A, Jones WJ, Dietz B, Rajagopalan R. Comparison of Markov Model and Discrete Event Simulation (DES) Techniques for HIV Disease. *Pharmacoeconomics* 2009 27(2):159-165.
- 77 Kirbach S, **Simpson KN**, Nietert PJ, Mintzer JE. A Markov model of the cost-effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease. *Clinical Drug Invest*. 2008 28(50):291-303.
- 76 Clancy DE, CE Dismuke, KM Magruder, **KN Simpson**, WD Bradford. Do Group Visits Lead to Lower Costs of Diabetes Care? *Am. J. Managed Care*. 2008 Jan; 14(1):39-44.
- 75 Bushard RL, Massey EB, Simpson TW, Arial JC, **Simpson KN**. Poly-pharmacy: Misleading but manageable. *Clinical Interventions in Ageing*. 2008 ; 1-9.
- 74 **Simpson KN**, Walter J, Jones, Rukmini Rajagopalan, Birgitta Dietz. Cost-effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France Italy and Spain. *Clin. Drug Invest*. 2007 27(12): 807-817.

- 73 Hubben JA, Bos JM, Veltman-Starkenburger CA, Stegmeijer S, Finnern HW, Kappelhoff BS, **Simpson KN**, Tramarin A, Postma MJ. Cost-Effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. *Cost Effectiveness and Resource Allocation* 2007 5:15; 1-9.
- 72 Mauldin PD, **Simpson KN**, Palesch YY, Spilker JS, Hill MD, Broderick JP, and the IMS III Investigators. Design of the Economic Evaluation for the Interventional Management of Stroke Trial. *Int. J. Stroke* 2008; 3(2): 138-144.
- 71 Lunsford SL, **Simpson KS**, Chavin KD, et al. Can Family Attributes Explain the Racial Disparity in Living Kidney Donation? *Transplant Proceed* 2007 39(5): 1376-80.
- 70 **Simpson KN**, Walter J. Jones, Rukmini Rajagopalan, Birgitta Dietz. Cost-effectiveness of lopinavir/ritonavir compared to atazanavir plus ritonavir in antiretroviral-experienced patients in the U.S.: Modeling the combined effects of HIV and Heart Disease. *Clin. Drug Invest.* 2007 27(7): 443-452.
- 69 **Simpson KN**, Luo MP, Chumney ECG, Mazyck J, King M, Brun S, Ashraf T. Cost Effectiveness of Lopinavir/r vs. Atazanavir in Treating Antiretroviral-Naïve Patients: Modeling the Combined Effects of HIV and Heart Disease. *Clin. Drug Invest.* 27(1):67-74, 2007.
- 68 Moeller KE. Barnes BJ. Stanley KM. Worrall CL. Lunsford SL. **Simpson KN**. Miller JG. Spencer AP. Compliance of an institution-specific alcohol withdrawal protocol with evidence-based practice guidelines. *Pharmacotherapy* . 2006 26(3):445-6.
- 67 Lunsford SL, **Simpson KS**, Chavin KD, et al. Racial Disparities in Living Kidney Donation: Is There a Lack of Willing Donors or an Excess of Medically Unsuitable Candidates? *Transplantation* 2006; 82(7): 876-881.
- 66 Okonofua EC, **Simpson KN**, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic Inertia Is An Impediment To Achieving The Healthy People 2010 Blood Pressure Control Goals. *J Hypertension*, 47(3):345-51, 2006.
65. Chumney ECG, Mauldin PD, **Simpson KN**. Charges for Hospital Admissions Attributable to Health Disparities for African American Patients in South Carolina During 1998-2002. *JNMA* 2006 98:5:690-95.
64. Taylor L, **Simpson K**, Bushard R, Reeves CB, Elkin TD, Fortson BL, Boll T, Patell S. Insurance barriers among childhood survivors of pediatric brain tumors: The case for neurocognitive evaluations. *J. Ped. Neurosurgery* 42(4):223-7, 2006.
63. Lunsford SL, **Simpson KN**, Chavin KD, Hildebrand RG, Miles LG, Shilling LM, Smalls GR, Baliga PK. Racial differences in coping with the need for kidney transplantation and willingness to ask for live organ donation. *Am. J. Kidney Dis.* 47(2):324-31, 2006 .
62. Brady KT, Sonne S, Anton RF, Randall CL, Back SE, **Simpson K**. Sertraline in the Treatment of Co-occurring Alcohol Dependence and Posttraumatic Stress Disorder. *Alcoholism: Clinical and Experimental Research* 29(3):395-401, 2005.
61. Book SW, Boehm RS, **Simpson KN**. Treating Alcoholics With a Co-Occurring Anxiety Disorder: A Markov Model to Predict Long Term Costs. *Dual Diagnosis* 2005 1(4):53-62.
59. Stanley KM. Spencer AP, Lunsford SL, **Simpson KN**, Miller JG, Worrall CL. Experience with an Adult Alcohol Withdrawal Syndrome Practice Guideline in Internal Medicine Patients. *Pharmacotherapy* 2005, (25)8.
58. **Simpson KN**, Luo MP, Chumney ECG, Sun E, Brun S, Ashraf T. Cost effectiveness of using lopinavir vs. nelfinavir as the first highly active antiretroviral therapy regimen for HIV infection. *HIV Clinical Trials* 2004 (5)5:294-304.
57. McBurney PG, **Simpson KN**, Darden PM. Potential cost savings of decrease emergency department visits through increased continuity in pediatric medical home. *Am Peds* 2004 4(3):204-8.
56. Chumney ECG, Biddle AK, **Simpson KN** et al. The effect of cost construction based on either DRG or ICD-9 codes or risk-group stratification on the resulting cost-effectiveness ratios. *J Pharmacoeconomics* 2004 22(18); 1209-16.

55. Killeen, TK, Brady, KT, Gold, P, **Simpson, K**, Tyson, C. Comparison of self-report and archival data abstraction of service utilization in a community sample of treatment seeking alcohol abusing individuals. *Drug and Alcohol Dependence* 2004;73:141-147.
54. Kozel FA, George MS, **Simpson KN**. Decision analysis of cost effectiveness of repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for treatment of non-psychotic severe depression. *CNS Spectrums* 2004 9(6):476-82.
53. Stanley KM, Amabile CM, **Simpson KN**, Couillard D, Norcross ED, Worrall CL. Impact of an alcohol withdrawal syndrome practice guideline on patient outcomes in the acute care setting. *PharmacoTherapy* 2003(23)7:843-54.
52. Siachos AT, Van Bakel A, Feldman D, Uber W, **Simpson KN**, Pereira N. Silent strokes in patients with heart failure. *J of Cardiac Failure*. 11(7):485-9, 2005.
51. Highland KB, Strange C, Mazur J, **Simpson KN**. Treatment of pulmonary hypertension: A decision analysis. *Chest* 2003 124(6):2087-2092.
50. Egede LE and **Simpson KN**. Epidemiology, treatment and costs of depression in adults with type-2 diabetes. *Expert Rev. Pharmacoeconomics Outcomes Res.* 2003 3(3) 89-100.
49. Egede LE, Zheng D, **Simpson K**. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. *Diabetes Care* 2002 25(3) 464-470.
48. Richter A, Hauber B, **Simpson K**, Mauskopf JA, Yin D. A Monte Carlo simulation for modeling outcomes of AIDS treatment regimens. *PharmacoEconomics* 2002 20(4):215-224.
47. Brady KT, Sonne SC, Malcolm R, Randall CL, Dansky BS, **Simpson K**, Brondino M. Carbamazepine in the treatment of cocaine dependence: Subtyping by affective disorder. *Experimental & Clinical Psychopharmacology*. 2002;10(30):276-285.
46. Chumney ECG, **Simpson KN**. The emerging role of the consumer in pharmaceutical pricing decisions. *Disease Management and Health Outcomes* 2001 (10) 2;1-4.
45. **Simpson KN**, Voit EO, Goodman R, Chumney ECG. Estimating the social and economic benefits of pharmaceutical innovations: Modeling clinical trial results in HIV-disease. *Research in Human Capital and Development* 2001 (14) 175-198.
44. Marshall DA, **Simpson KN**, Earle CC, Chu CW. Economic decision analysis model of screening for lung cancer. *Eur J Cancer* 2001 (37) 1759-1767.
43. Marshall DA, **Simpson KN**, Earle CC, Chu CW. Potential cost effectiveness of one-time screening for lung cancer in a high-risk cohort. *Lung Cancer* 2001 32(3) 227-236.
42. Youle M, Holzer C, **Simpson KN**, de Clerq K, Miller V. HIV-1 drug resistance testing: Health outcomes. *Antiviral Therapy* 2000, 5(2):113-115.
41. Helm, JF, Russo MW, Biddle AK, **Simpson KN**, Ransohof DF, Sandler RS. Effectiveness and economic impact of a concerted effort to implement mass fecal occult blood screening. *Am J Gastroenterology* 2000 95(11):3250-3258.
40. Mauskopf JA, Tolson JM, **Simpson KN**, Pham SV, Albright J. The impact of zidovudine-based triple combination therapy on an AIDS drug assistance program *JAIDS*, 2000; 23:302-313.
39. Biddle AK, **Simpson KN**. Clinical benefits, budget impacts, and cost effectiveness of managing HIV+ patients with triple combination therapies in five countries. *Value in Health* 2000; (3)3 186-201.
38. Marshall D, **Simpson KN**, Martinot M, McHutchison J, Perrillo R, Marcellin P, Banach M, Pawlotsky J-M. Economic analysis of early serum hepatitis C virus RNA testing in patients with chronic hepatitis C on interferon therapy. *J. Drug Assessment*, 2000; 3:47-62.

37. McLaughlin, CP, **Simpson, KN**. Operations management theory and the management of medical technology. *Int. J. Healthcare Technology and Management*, 2000 2(1/2/3/4) 181-203.
36. Marshall DA, **Simpson KN**, Norton EC, Biddle AK, Youle M. Measuring the Effect of Clinical Guidelines on Patient Outcomes. *Intl. J. Technology Assessment in Hlth. Care*, 2000 3(1) 47-63.
35. Ragnarson KT, Moses LG, Clarke WR, Daling JR, Garber SL, Gustafson CF, Holland AL, Jordan BD, Riddle MA, Roth EJ, Seltzer MM, **Simpson KN**, Small SL, Therrien B, Wexler BE Yawn BP. Rehabilitation of persons with traumatic brain injury. *JAMA* 1999, 282(10):997-983.
34. Shih YCT, Kauf TL, Biddle AK, **Simpson KN**. Incorporating problem-based learning into a lecture-based pharmacoeconomics course. *Am. J. of Pharmaceutical Ed.* 1999, Vol 63, Summer 152-159.
33. Biddle AK, **Simpson KN**. Modeling the cost effectiveness of nevirapine triple combination therapy and dual combination therapy for the treatment of HIV disease in the United Kingdom. *J. Medical Economics* 1999; 2: 85-105.
32. Youle M, Trueman P, **Simpson K**. Health economics in HIV disease. *PharmacoEconomics* 1998 14 (supl 4);1-12.
31. Neymark N, W Kiebert, K Torfs, P Fayers, R Gelber, G Guyatt, B Hillner, P Kind, D Machin, E Nord, D Osoba, D Revicki, K Schulman, **K Simpson**. Methodological and statistical issues of Quality of Life (QoL) and economic evaluation in cancer clinical trials: Report of a workshop. *European J of Cancer* 1998 34(9):1317-1333.
30. Mauskopf J, Lacey L, Kempel A, **Simpson KN**. The cost effectiveness of treatment with Lamivudine and Zidovudine compared to Zidovudine alone: A comparison of Markov model and trial data estimates. *Am J Managed Care* 1998 4(7):1004-1012.
29. Myers ER, Thompson JW, **Simpson KN**. Mandatory versus voluntary screening of pregnant women for human immunodeficiency virus: a cost-effectiveness analysis. *Obstetrics & Gynecology* 1998, 91(2):174-181.
28. Halperen M, Palmer CS, **Simpson KN** et al. The marginal cost effectiveness of using three laboratory test production processes for the management of cardiac surgery patients in intensive care units. *Am J Medical Quality* 1998 13(1):3-12.
27. **Simpson KN**, Coughlin M, Eron J, Bussell J. Idiopathic Thrombocytopenia Purpura: Treatment patterns and an analysis of costs associated with intravenous immunoglobuline (IVIG) and anti-D therapy. *Seminars in Hematology* 1998, 35(S1):58-64.
26. Portela M, **Simpson KN**, Guess H, Sen PK, Kilpatrick K. Markers and cofactors for progression of patients with HIV+ disease. *J Mem Inst Oswaldo Cruz*, 1997 92(4):437-457.
25. Almasdottir AB, Hartzema AG, Bush PJ, **Simpson KN**, Zimmer C. Children's attitude and beliefs about illness and medicines. *J Soc. Adm. Pharmacy* 1997 14:1 26-39.
24. Chancellor J, Hill A, **Simpson K**, Yule M. Cost effectiveness of 3TC and ZDV in patients with HIV-Disease. *PharmacoEconomics* 1997 12:1 1-13.
23. Shugars DA, Benson K, White RP, **Simpson KN**, Bader JD. Developing a measure of patient perceptions of short-term outcomes of third molar surgery. *J Oral Maxillofac Surg* 1996 54: 1402-1408.
22. McLaughlin CP, **Simpson KN**. The new realities in health care technology assessment in U.S. institutions. *Intern. J. Technology Management* 15(3-5):507-521, 1998 .
21. **Simpson KN**. Design and assessment of cost effectiveness studies in AIDS populations. *JAIDS* 1995 Vol 10 Supp.4 S28-S32.

20. Zarkin GA, Bala MV, Wood LL, Bennett CL, **Simpson KN**, Dohn MN. Estimating the Cost-Effectiveness of Atovaquone versus Intravenous Pentamidine in the Treatment of Mild- to Moderate-PCP Patients. *Pharmacoeconomics* 1996 9:6 525-534.
19. **Simpson KN**. Modeling with clinical trial data: Getting from the data researchers have to the data decision makers need. *Drug Information J.* 1995 29:4 1431-1440.
18. Revicki, D.A., **K.N. Simpson**, A.W. Wu and R.L. LaVallee. Quality of Life in Rifabutin Prophylaxis for Mycobacterium Avium Complex in Persons with AIDS. *Quality of Life Research* 1995 Vol 4 309-318.
17. DesHarnais SI and **Simpson KN**. Antiviral drug use in hospitalized patients with herpes infections: Variations in practice patterns. *Am J Medical Quality* 1996 11:1, 33-42.
16. **Simpson KN**, King C, Lynch S, Rentz A, Stevens C. Cost of Ultrasound Screening in Low-Risk Pregnancies. *J Mater Fetal Invest* 1995 5 175-177.
15. **Simpson K.N.** and Lynch S.R. Cost savings from the use of antenatal steroids to prevent respiratory distress syndrome and related conditions in premature infants. *Am J Obstet Gynecol* 1995; 173:316-21.
14. **Simpson, K. N.**, A. Biddle, NR Rabinovich. A Model for Estimating the Impact of Changes in Children's Vaccines. *Am J Pub Hlth* 1995 85:12 1666-1672.
13. Luce, B.R. and **K.N. Simpson**. Methods of Cost Effectiveness Research: Areas of Consensus and Debate. *Clinical Therapeutics* 1995 17:1 109-125.
12. Brown RE, Miller B, Taylor WR, Palmer C, Bosco L, Nicola R Zellinger J and **Simpson KN**. Health Care Expenditures for Tuberculosis in the United States. *Arch Intern Med* 1995 155 1595-1600.
11. **Simpson K.N.** Problems and Perspectives on the Use of Decision-Analysis Models for Prostate Cancer. *J Urology* 1994, 152; 1888-1893.
10. **Simpson K.N.** Outcomes research in prostate cancer- Editorial. *J Urol* 1994, 152; 1865.
9. Knechten, H nach **KN Simpson**. Argumente Fur die Kombination von Azidothymidin und Zalcitabin. Springer: *Belage fur Internisten*, pp 17-18, 1994.
8. **Simpson, K.**, F. Andersson, A. Shakespeare, I. Oleksy, and E.J. Hatzianreou. Cost Effectiveness of Antiviral Treatment with Zalcitabine in Combination with Zidovudine for AIDS Patients with CD4 counts <math>300\text{ per mm}^3</math> in Five European Countries. *Pharmacoeconomics* 1994, (6)6; 553-562.
7. LaVallee, RW and **Simpson, KN**. Working for the Government: PAs in the Department of Veterans Affairs. *J Am Acad Physician Assist*, 1993, 6:2 135-9.
6. Kaluzny, AD, CP McLaughlin, and **KN Simpson**. Applying Total Quality Management Concepts in Public Health Organization. *Public Health Reports*, 1992, 257-264.
5. **Simpson, K.N.**, G. Stoodt, S.G. Sherman, and P. Rochester. Strategic Planning for Public Health: Cancer Control in North Carolina. *Evaluation and Program Planning: Int J*, 1992, Vol 15, pp 383-393.
4. DesHarnais, SI and **KN Simpson**. Indices for Monitoring Hospital Outcomes in Developed Countries. *Health Policy*, 1992, Vol 21, pp 1-15.
3. **Simpson, K.N.** and Lyle B. Snider. Informing Mammography Coverage Debate: Results of Meta Analysis, Computer Modeling, and Issue Analysis. *Intl J Tech Ass Hlth Care*, 1991, Vol 7, No. 4, pp 616-631.
2. **Simpson, KN**, AD Kaluzny, and CP McLaughlin. Total Quality and the Management of Laboratories. *Clin Lab Mgt Rev*, 1991, pp 448-462.

1. **Simpson, K.N.** and J.E. Veney, "National Indicators for Health for All," *Soc Indicators Res*, Oct. 20, 1988, pp. 533-548.

#### Dissertation

**Simpson, K.N.**, Analyzing the Effect of Public Prevention Programs on Low Birth Weight in North Carolina Counties." Doctoral Dissertation, 1988.

#### Books and Chapters

Simpson AN, **Simpson KN**. Chapter 11. Comparative Effectiveness. In *Medical Epidemiology: Population Health and Effective Health Care 5<sup>th</sup> Edition*. Greenberg RS Ed. 2015 Lange Basic Science.

Chumney ECG, **Simpson KN** eds. *Methods and Designs for Outcomes Research*. ASHP 2006. ISBN: 1585281115

**Simpson KN** and McLaughlin CP. "Strategic Decision Making, Economic Analysis, and TQM" in McLaughlin, C.P. and A.D. Kaluzny (eds.), *Continuous Quality Improvement in Health Care, Second Edition*. Gaithersburg, MD: Aspen Publishers Inc., 1999.

McLaughlin CP, **Simpson KN**. *Operations Management Theory and the Management of Medical Technology* 37 pp, forthcoming

**Simpson KN** and McLaughlin CP. "Strategic Decision Making, Economic Analysis, and TQM". In *Continuous Quality Improvement in Health Care*. Eds. McLaughlin CP. and Kaluzny AD. Gaithersburg, MD: 1994, pp 148-166.

**Simpson KN**, McLaughlin CP, and Kaluzny AD. "Planning, Organizing, and Leading Continuous Improvement". In *Continuous Quality Improvement in Health Care*. Eds. McLaughlin CP. and Kaluzny AD. Gaithersburg, MD: 1994, pp 169-186.

**Simpson KN**, Kaluzny AD, and McLaughlin CP. "Total Quality and the Management of Laboratories". In *Continuous Quality Improvement in Health Care*. Eds. McLaughlin CP. and Kaluzny AD. Gaithersburg, MD: 1994, pp 265-276.

McLaughlin, CP and **Simpson, KN**. "Does TQM/CQI Work in Health Care?". In *Continuous Quality Improvement in Health Care*. Eds. McLaughlin CP. and Kaluzny AD. Gaithersburg, MD: 1994, pp 33-46.

Kaluzny AD, McLaughlin CP, and **Simpson KN**. "Applying Total Quality Management Concepts to Public Health Organizations". In *Continuous Quality Improvement in Health Care*. Eds. McLaughlin CP. and Kaluzny AD. Gaithersburg, MD: 1994, pp 277-287.

McLaughlin CP and **Simpson KN**. "Holston Valley Hospital and Medical Center: Case 2". In *Continuous Quality Improvement in Health Care*. Eds. McLaughlin CP. and Kaluzny AD. Gaithersburg, MD: 1994, pp 335-360.

**Simpson KN**, DesHarnais SI, Jacobs A, and Menapace A. "Methods for Defining Medical Service Areas". In *Geographic Methods for Health Services Research*. Eds. Ricketts TC, Savitz LA, Gesler WM, and Osborne ON. Lanham, MD: 1994, pp 207-233.

## **REPORTS and MONOGRAPHS**

**KN Simpson**, EG Chumney, AC Simpson. Predicting High Cost for Schizophrenia Patients on Medicaid. Report to Comprehensive NeuroScience, Inc. August 8, 2004

Riesebrough N, **Simpson KN**. Economic evaluation of lopinavir/ritonavir in the treatment of human immunodeficiency virus. Final Report 2-23-2001. The HOPE (Health Outcomes and PharmacoEconomics) Research Centre, University of Toronto, ON m4n 3M5.

Report of the Panel for Consensus Development Conference on Rehabilitation of Persons with Traumatic Brain Injuries. National Institutes of Health, Bethesda MD, October 26-28, 1998.

Biddle AK, **Simpson KN**. Pediatric Allergy Learning Study (PALS): An evaluation of the effects of Claritin on seasonal allergic rhinitis-associated emotional and school performance impairments in children who are at least 7 and less than 11 years of age: An outcomes study. ACER/Excel and Schering Corp. December 1998.

Consortium for Spinal Cord Medicine. Prevention of Thromboembolism in Spinal Cord Injury. Clinical Practice Guidelines for Spinal Cord Medicine. Paralyzed Veterans of America, Washington DC, February 1997.

Consortium for Spinal Cord Medicine. Acute Management of Autonomic Dysreflexia: Adults with Spinal Cord Injury Presenting to Health Care Facilities. Clinical Practice Guidelines for Spinal Cord Medicine. Paralyzed Veterans of America, Washington DC, February 1997.

Committee on Guideline Development. Standards for the Development of Practice Guidelines in VA Health Systems V.A. Institute for Quality Management, Durham, N.C. 1996.

**Simpson KN**. A Strategic Model for Predicting Cost Effectiveness of Drug X to Inform Phase I Trial Decisions. Confidential Client. Jan. 1, 1996.

**Simpson KN**, Iztler R. Exploratory Economic Analysis of Data from Randomized Clinical Trials of Antiretroviral Therapy in HIV Disease Populations and Recommendations for Future Study Design and Analysis Protocols . Confidential Client. March 5, 1996.

**Simpson KN**. Costs and Expected Health Outcomes from the First Year of Inivrase Combination Therapy in Canada with Cost Estimates for Individual Provinces. Report to Hoffman-La Roche Limited, Toronto Canada. February 27, 1996.

**Simpson KN**, LaVallee RL, Portela M. Outcomes and Costs of Monotherapy with AZT vs. Combination Therapy with Saquinavir and ddC in U.S. Patients with HIV-Disease. Report to Roche Laboratories, Nutley NJ. Department of Health Policy and Administration, UNC School of Public Health. January 20, 1996.

**Simpson KN**, Coughlin C, LaVallee RL, Branthwaite D, Calhoun E. Cost Comparisons of IVIG and WinRho and Treatment Patterns for Patients with ITP. MEDTAP International Inc. Arlington VA. December 29, 1995.

**Simpson KN**, Flepp M, Hirschel B. Cost and Consequences of Adding Inivrase to Current Antiviral Therapy for Swiss Patients. MEDTAP International, Arlington VA. December 27, 1995.

**Simpson KN**, Luce BR. Types and uses of cost-effectiveness studies. Background paper. State-of-the-art conference: Technology Assessment: A Tool for Technology Management and Improved Patient Outcomes. VA Office of Research and Development and Foundation for Health Services Research. Washington DC. Jan. 1995.

**Simpson, KN** and RL LaVallee. Technical Effectiveness and Economic Efficiency of Point-of-Care Testing for Critically Ill Patients: GEM Premiere versus Usual Laboratory Testing Procedures. P24838. Arlington VA, Battelle Medical Technology and Policy Research Program, 1994

Brown R, Palmer CS and **Simpson KN**. The Cost of Tuberculosis in the United States in 1991. Final report to Centers for Disease Control and Prevention. Battelle Medical Technology and Policy Research Center, 1994.

**Simpson, K.N.**, C. King, S.R. Lynch, A. Rentz and C. Stevens. Cost of Ultrasound Screening in Low-risk Pregnancies. Final report to the National Institute of Child Health and Development 1994.

**Simpson, K.N.**, S.R. Lynch, F.E. Mebane, T.J. Hamby and C. Paramore. Cost Effectiveness of the Use of Antenatal Steroids to Prevent Respiratory Distress Syndrome and Related Conditions in Premature Infants. Final report to the National Institute of Child Health and Development 1993.

**Simpson, Kit N.** and R. L. LaVallee. Cost Effectiveness of Using Rifabutin for the Prevention of Mycobacterium Avian Complex (MAC) Bacteremia in AIDS Patients with CD4 <200 per mm<sup>3</sup> in the United Kingdom. Washington, DC: Battelle Medical Technology and Policy Research Center, 1993.



Luce, Bryan and **Kit N. Simpson**. Methods of Cost Effectiveness Research: Areas of Consensus and Debate. Report to the Pharmaceutical Manufacturers Association. Washington, DC: Battelle Medical Technology and Policy Research Center, 1993.

**Simpson, K.**, F. Andersson, A. Shakespeare, I. Oleksy, and E.J. Hatziandreu. A Cost Effectiveness Study of Antiviral Treatment with Zalcitabine in Combination with Zidovudine for AIDS Patients in Italy with CD4 counts 300 per mm<sup>3</sup>. Washington, DC: Battelle Medical Technology and Policy Research Centre, 1993.

**Simpson, Kit N.**, A. Biddle and D. Boldy. A Model for Estimating the Impact of Research Investment Choices for the Children's Vaccine Initiative. Final Report of Phase I. National Institutes of Health order No. 263-MD-14293, 1993.

**Simpson, Kit N.**, and Ruth E. Brown. Cost Effectiveness of Prostate Specific Antigen and Digital Rectal Examination in the Detection of Prostate Cancer. Washington, DC: Battelle Medical Technology Assessment and Policy Research Centre, 1993.

**Simpson, Kit N.** and Rebecca L. LaVallee. Cost Effectiveness of Using Rifabutin for the Prevention of Mycobacterium Avian Complex (MAC) Bacteremia in AIDS Patients with CD4 <200 per mm<sup>3</sup>. Washington, DC: Battelle Medical Technology and Policy Research Centre, 1993.

**Simpson, K.**, F. Andersson, A. Shakespeare, I. Oleksy, and E.J. Hatziandreu. A Cost Effectiveness Study of Antiviral Treatment with Zalcitabine in Combination with Zidovudine for AIDS Patients with CD4 Counts 300 per mm<sup>3</sup>: Base Model and Switzerland. Washington, DC: Battelle Medical Technology and Policy Research Centre, 1992.

**Simpson, K.**, F. Andersson, A. Shakespeare, I. Oleksy, and E.J. Hatziandreu. A Cost Effectiveness Study of Antiviral Treatment with Zalcitabine in Combination with Zidovudine for German AIDS Patients with CD4 Counts 300 per mm<sup>3</sup>. Washington, DC: Battelle Medical Technology and Policy Research Centre, 1992.

**Simpson, K.**, F. Andersson, A. Shakespeare, I. Oleksy, and E.J. Hatziandreu. A Cost Effectiveness Study of Antiviral Treatment with Zalcitabine in Combination with Zidovudine for AIDS Patients in France with CD4 counts 300 per mm<sup>3</sup>. Washington, DC: Battelle Medical Technology and Policy Research Centre, 1992.

**Simpson, K.**, F. Andersson, A. Shakespeare, I. Oleksy, and E.J. Hatziandreu. A Cost Effectiveness Study of Antiviral Treatment with Zalcitabine in Combination with Zidovudine for AIDS Patients in the United Kingdom with CD4 Counts 300 per mm<sup>3</sup>. Washington, DC: Battelle Medical Technology and Policy Research Centre, 1992.

Veney, JE, KN **Simpson**, and JC Jacobson. Evaluation Design for Community Programs for Clinical Research in AIDS Final Report Submitted to the Community Clinical Research Branch, Division of AIDS, NIAD August 27, 1991.

Veney, JE, KN **Simpson**, and JC Jacobson. Cost Analysis for the Evaluation Design for Community Programs for Clinical Research in AIDS. Community Clinical Research Branch, Division of AIDS, NIAD October 18, 1991.

**Simpson, K.N.** and K.E. Kilpatrick. Final Report on the Reevaluation of the Florida Demonstration Project REACH: Rural Efforts to Assist Children at Home. Report to The Robert Wood Johnson Foundation, June, 1990.

DesHarnais, S. and **K. Simpson**. Small Area Variations in Utilization and Outcomes for Hospital Care Among Medicare Beneficiaries: Results of Analysis for North Carolina. August 1989.

**Simpson, K.** and L. Snider. Cost Effectiveness of Mandating Third Party Reimbursement of Mammography Screening for North Carolina Women 50-65 years of Age, Final Report to the N.C. Division of Health Services, Adult Health Services Section. Sub-contract for NCI Grant "Data Based Interventions for Cancer Control, 1989.

**Simpson, K.** and A. Fontain. Impact of Management Training for In-Charge Nurses on Rural Clinics in Kenya, Final Evaluation Report. INTRAH and USAID, 1988.

## Proceedings

Voit EO, Schwacke LH, **Simpson KN**. Application of S-distributions to resource use and cost data in clinical and economic studies. Proceedings of the 2000 Joint Statistical Meeting. Indianapolis, August 13-17, 2000.

**Simpson KN**. Modeling in Cancer. Invited paper. The First European Conference on the Economics of Cancer. Brussels November 19-21, 1997. EORTC: European Organization for Research and Treatment of Cancer, Brussels, Belgium, 1997.

McLaughlin CP, **Simpson KN**, Johnson SP. A methodology for studying learning rates by organizational form in U.S. health care services: The example of premature labor. Proceedings of the European Operations Management Association, London Business School, 1997.

**Simpson, K.N.** The use of cost effectiveness analysis to inform investment decisions on research on the artificial heart and other evolving technologies. National Heart, Lung and Blood Institute. Proceedings from Expert Workshop. Bethesda M.D. January 23-24, 1993.

**Simpson, K.N.** Issues in decision modeling for early stage prostate cancer. Symposium on Early Prostate Cancer Treatment. American Urological Association, American Cancer Society in cooperation with the National Cancer Institute. Crystal City V.A. December 3-5 1993.

**Simpson, K.N.**, C. King, S.R. Lynch, A. Rentz and C. Stevens. Cost of ultrasound screening in low-risk pregnancies. Proceedings. Symposium on the results of the RADIUS trial. National Institute of Child Health and Development 1993.

**Simpson KN** and DesHarnais SI. Criteria for selecting an approach to medical service area definition. Proceedings. 1991 Public Health Conference on Records and Statistics. National Center for Health Statistics. Hyattsville MD 20782.

Pathman, D.E., T.R. Konrad, and **K.N. Simpson**, "Utilization Review, Clinical Protocols, and Physician Satisfaction." Proceedings of the Health Services Research Fellowship Symposium. Dept. Of Family Medicine and The Health Services Research Center, University of North Carolina at Chapel Hill 1990.

## RESEARCH

### **Current Research**

HRSA-U66RH31458 Ford (PI) 09/30/2017-9/29/2020

#### ***Telehealth Center of Excellence***

To develop a Telehealth Center of Excellence, including evaluation of the effects of tele-health on improvement of local and federal healthcare spending, assessment of telehealth adoption and utilization, and issues informatics and in systems standardization.

Role: Director of economic analysis functions.

PCS-1402-10867 Simpson (Co-PI) 07/01/2015 – 06/30/2020

Patient-Centered Outcomes Research Institute

#### ***Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients: A Multi-Site Pragmatic RCT***

The goal of this study is to use EHR workflow modifications to screen for and test combined screening and physical therapy in the primary care setting to prevent progression of acute back pain to a chronic condition.

Role: Site Co-PI

University Research Core Simpson (PI) 11/01/2015 – 6/30/2018

MUSC Provost for Research

#### ***Comparative Effectiveness Data Analytics Research Resource***

The goal is to develop and direct a new university research core that will be the custodian of "Big Data" administrative data sets and provide consultation and analytical support for faculty and students to use these data for research.

Role: Principal Investigator

U01 MD0111281

Kanter (PI)

07/01/2016 – 06/30/2022

NIH/NHLBI

***Implementation of a Sickle Cell Enhanced Novel Care Network in South Carolina (iSCENSC)***

This project, iSCENSC (Implementation of a Sickle Cell Enhanced Novel Care Network in South Carolina) is designed to develop a patient registry and evaluate intervention effectiveness for achieving full implementation of the SC2 network and to determine if the hub and spokes model of care increases access to quality care for individuals with SCD and produces findings sufficient to identify replicable methods for optimal care enrichment especially in rural populations.

Role: Co-Investigator

U19HD089875 Stanton, Naar-King, Parsons (PI)

09/30/2016 – 05/31/2021

Wayne State University/NIH/NICHD

***Scale It Up: Effectiveness-implementation Research to Enhance HIV-related Self-management among Youth***

In this U19 study, the interdisciplinary research team is committed to working with HIV-infected youth and youth at risk of infection to increase self-management skills—and to expediting the research development phase such that effective programs can serve the needs of youth as soon as possible.

Role: Principal Investigator of Sub-award for economic studies

HR-7-302 Ball (PI)

08/01/2016 – 08/31/2017

SC DHEC / CDC

***SC Prescription Drug Overdose Prevention for States***

The goals are to use the SC prescription data registry and archival billing data bases to identify the intended and unintended consequences of South Carolina payer policies that require prescribers of controlled substances to participate in the state's Prescription Drug Monitoring Program (SCRIPTS), and also to implement and evaluate Academic Detailing educational outreach services for prescription drug overdose prevention.

Role: Co-Investigator

Duke Endowment

Ford (PI)

2/01/14 – 1/31/17

*Telemedicine in ICU care.* Implementation and evaluation of the effectiveness of telemedicine in SC hospital ICUs.

Role: Co-investigator for EMR data assessment and analysis.

**Previous Research**

AbbVie

Simpson (PI)

04/15/14 – 06/30/15

*Estimating Cost of Cure for HCV in 20 developed countries.* This study uses integration of evidence for combination therapy for hepatitis C infection (HCV) combined with cost analysis of archival billing data to estimate the cost per patient successfully treated for HCV in developed countries. Role: PI.

U01 NS054630

Palesh (PI)

09/15/05 – 08/31/13

NIH/National Institute of Neurological Disorders and Stroke

*The ALIAS/IMS3 Study.* This is a pilot study and large trial to assess outcomes for stroke therapy.

Role: Co-investigator

R01 1RC1MD004405-01

Ford (PI)

12/01/09 – 11/30/12

NIH/NCMHD

Critical Care Excellence in Sepsis and Trauma-CREST

CREST uses transformational approaches to address rural health disparities by combining an educational program with telemedicine consultation at rural SC hospitals to improve outcomes in sepsis and trauma. Dr Simpson is the leader of the impact evaluation using EMR and archival billing data for the sepsis intervention. Role: Co-Investigator

R01 DK062596

Baliga (PI)

07/01/07 – 06/31/12

NIH/NIDDK

*A Program to Increase Living Donations in African Americans*

This program will identify and increase the live organ donation rates among African Americans by aiming to: (1) Train educators to work with African American patients and families; (2) Identify potential African American donors early and provide appropriate education; and (3) Utilize trained educators to assist patients and their families in navigating the transplant process. Role: Co-Investigator

Internal Project Moran (PI) 09/01/08 – 06/30/10  
MUSC General Internal Medicine & Geriatrics  
*Data Mining for Medical Resident's Quality Improvement Project*  
The goal is to a) provide methodological support for residents and faculty in quality and outcomes research, and b) analyze hospital data to improve patient outcomes. Role: Expert advisor/mentor; Medical Director of eCare Net Data Mining and Internal Medicine Resident Research Training Faculty

D57HP08309 Jacques (PI) 07/01/07 – 06/30/10  
Health Resources and Services Administration  
*Physician Assistant Training in Primary Care*. The purpose is the development of a model program that offers a 2-year academic fellowship for a recent PA graduate with at least one year of clinical experience.  
Role: Co-Investigator

Abbott Laboratories. Simpson (PI) 07/16/09 – 09/30/10  
*Economic Estimates Based on ACTG5142 for Five Countries*  
The goal of this study is to use previously developed economic HIV-disease ACTG5142 Markov model for the US to examine the incremental cost effectiveness of Kaletra when compared to an NNRTI-based regimen in antiretroviral-naïve individuals in the UK, Germany, France, Italy and Spain.  
Role: Principal Investigator

Abbott Laboratories. Simpson (PI) 04/15/09 – 10/14/10  
*Characteristics of Adverse Events in HIV Clinical Trials and their Effects on HRQL and Trial Discontinuation: A Pooled analysis of clinical trial data*  
The goal of the project is to examine the prevalence and persistence of gastrointestinal, neuro-psychiatric and pain adverse events reported in antiretroviral trials, and their effects on quality of life and propensity for early discontinuation. Role: Principal Investigator

Abbott Laboratories. Simpson (PI) 03/18/09 – 06/17/10  
*Economic Models of Kaletra for Europe*  
The goal of the project is to examine the cost effectiveness of Kaletra capsules when compared to boosted Atazanavir using the previously developed economic HIV-disease CASTLE Markov model for the US to estimate outcomes for the UK, Germany, France, Spain and Italy.  
Role: Principal Investigator

Simpson (PI), Abbott GmbH & Co, Ludwigshafen, Germany 06/01/08 - 03/31/09  
*Model to predict cost and consequences of 2<sup>nd</sup> line antiretroviral AIDS therapy in Africa based on the DART study*. Develop and Excel model of AIDS under competing mortality and morbidity of malaria and tuberculosis to estimate budget impact, disability-adjusted survival, number of orphans, number of children not in school, rural farm production hours lost, and medical and funeral cost to urban employers for Uganda and one other TBD country in Africa.

Simpson (PI), Abbott Laboratories, West Chicago Ill. 04/01/08 - 03/31/09  
*Cost effectiveness analysis based on the CASTLE study*. Using the AIDS Markov and Discrete Event Simulation models to estimate costs, consequences, and budget impacts for antiretroviral-naïve patients in the US.

Simpson (PI), MUSC 04/15/07 – 04/14/08  
*CTSA Pilot Study to develop a discrete event model to estimate impacts of changes in stroke treatments in SC*.  
This study uses ARENA discrete event modeling to estimate changes in outcomes and costs for SC if tPA use was increased through a TeleStroke Program, ER stroke team implementation, and other interventions to decrease the morbidity and cost resulting from acute ischemic stroke. \$38,000

Baliga (PI) 07/01/2007-06/30/12  
*A Program to Increase Living Donations in African Americans*  
The goal of the application is to conduct a study to test the hypothesis that live kidney donation in African Americans will increase with: The utilization of educators who are professionally trained to work with African-American families, early identification and education of African-American donors in potentially high-yield settings, and navigation of the potential donors through the complex evaluation process by these educators.  
Simpson Investigator 10% effort.

Simpson (PI), Neuronetics 01/08/06 – 01/07/08  
*Cost effectiveness of trans-cranial magnetic stimulation in severe depression*.

An economic analysis of data from three clinical trials for depression for the purpose of reimbursement approval by funding agencies.

Nahas Z (PI), Cyberonics 04/08/07 – 03/30/08  
*To design a synthetic placebo control group from archival data to compare outcomes from vagus nerve stimulation treatments for severe depression.*  
Role: Co-PI 10% effort

Palesh Y (PI) 09/15/05 – 05/31/10  
NIH/National Institute of Neurological Disorders and Stroke  
*The ALIAS/IMS3 Study.* This is a pilot study and large trial to assess outcomes for stroke therapy.  
Simpson Role: Co-investigator 5% effort Yr 3 budget \$113,482

Morrisette D. (PI) 08/01/06- 06/30/08  
*Clinical trial of elastic and inelastic lumbar-sacral support*  
Simpson Co-Investigator

Simpson (PI), Exponent 07/01/06-07/30/07  
Supitrol *Clinical Trial of Obesity Interventions*  
Outcomes trial testing compound to prevent patient drop-out from weight loss regimens.

Simpson (PI), Abbot Labs II Amendment 04/08/06 – 04/14/08  
*Discrete Event Simulation Model of Kaletra and Atzanavir*  
The purpose of the study is to compare a previously developed AIDS model to a new discrete event model for estimating the long-term outcomes of competing highly active antiretroviral therapies (HAART).

RO1 DK062596 Baliga (PI). 09/15/02 – 06/30/07  
NIH/National Institute of Diabetes, Digestive and Kidney Disease  
*A Program to Increase Living Donations in African Americans*  
The major goals of the project are to (a) assess specific barriers to live organ donations in African-American kidney transplant patients and their families, and (b) implement an educational intervention program to address these concerns and to eventually improve live organ donation rates among this population.  
Role: Co-Investigator 5% Effort (MUSC Project #84144) Direct costs: \$150,000

Corporate Contract Simpson (PI). Boehringer Ingleheim Pharmaceuticals, Inc. 06/01/02 - 07/30/06  
*Economic and Quality of Life Component for the Phase III Clinical Trials of Tipranavir*  
The goal of the project is to design economic and quality of life studies to complement Phase III clinical trial data collection in multinational studies, and to perform the economic analysis required for approval and pricing. Role: Principal Investigator

Principal Investigator (Abbott Labs Project #84528) 01/01/2006 – 04/14/2007  
Discrete Event vs. Markov Modeling Comparing Kaletra and Atzanavir in HIV-disease.  
The major goal of the project is to compare the performance of two types of mathematical models to assess differences in patient outcomes on combination regimens containing Kaletra vs. Atzanavir. \$121,000

RO1 MH066004. Santos (PI) 9/18/2002-7/31/2007  
Schizophrenia Liability Genes Among African Americans. Dr. Simpson is an investigator in charge of the data collection and quality measures. National Institute of Mental Health.  
Role: Co-Investigator 5% effort.

U01 NS054630 Palesh (PI). 9/15/2005-5/31/2010  
NIH/National Institute of Neurological Disorders and Stroke. The ALIAS/IMS3 Study  
Pilot study and large trial to assess outcomes for stroke therapy.  
Role: Co-investigator 5% Effort (MUSC Project # 05070890) Direct costs: \$791,155

Investigator. EXPORT Center on Metabolic Syndrome: Investigator Development Core. Research mentor for minority faculty. . NIH National Center for Minority Health Disparities 1P60 MD000267. 9/30/0- 8/31/07

Investigator. Southeastern Node, National Institute on Drug Abuse's Clinical Trial Network (CTN). As the economist for the node, she will provide methodological support for the design of economic and health services research studies and consultation for analysis of resource use and cost data. 10/1/00-9/30/05

Principal Investigator. Effects of adherence to ARV regimens on outcomes and cost in HIV-disease. GlaxoSmith-Klein. 9/16/04-7/31/05.

Principal Investigator. Two economic and quality of life "piggy-back" trials to complement the multinational Phase III clinical trials of Tipranavir salvage therapy. Boehringer Ingelheim 08/15/02-08/14/05.

Project Leader. Economic Access to Antiretroviral Prescription Drugs and Adherence to ARV Guidelines for African American Medicaid Enrollees with HIV-Disease in South Carolina. Study to identify black Medicaid patients with HIV-disease who appear to receive sub-optimal ARV therapy, and providers who have few HIV patients, and design a process to improve ARV care in S.C. Program Grant for Understanding and Eliminating Health Disparities from Agency for Healthcare Research and Quality HS-00-003. Total Project Direct Costs: \$534,900. 10/01/2000 to 10/31/2005

Co-Project Leader: Improving Care for High Risk Minority Patients with Chronic Illnesses by Using Pharmacist Consultations to Follow up on Missed Prescription Refills. Study will examine the impact of using a commercial pharmacy order-entry software program to identify patients at high risk for missed prescriptions, and the use of pharmacist counseling to improve medication adherence. The interventions will be aimed at for patients with hypertension, heart failure, diabetes, and/or depression. Program Grant for Understanding and Eliminating Health Disparities from the Agency for Healthcare Research and Quality HS-00-003. Total Project Direct Cost: \$375,682. 10/01/2000- 10/31/2005

Principal Investigator. Economic evaluation of Kaletra and Atazanavir. Abbott Laboratories. 7/1/2003- 12/31/2004.

Co-Principal Investigator: Cost effectiveness of cervicography vs. colposcopy in high-risk women in SC public health clinics. Model the cost effectiveness of using screening cervicography in women with positive PAP smears. Department of Defense/Hollings Cancer Center. Total Direct Costs \$93,702. 06/01/01-05/30/02.

Principal Investigator: S-Distribution Pilot Study. Develop and program a maximum likelihood estimator capable of testing the differences between two S-distributions, and use this estimator to reanalyze outcome and cost data from clinical trials to test the ability of this approach to improve study power to detect important differences in outcomes for measures with severely skewed and/or bimodal distributions. Funding for programming support. University Research Committee, MUSC. Total Direct Costs: \$18,000. 5/01/2000-4/31/2001.

Principal Investigator: Pilot Study for Standardized Indicators of Cancer Control Impact. This study will develop and pilot test a set of standardized indicators for four major cancers (breast, cervical, colon, and prostate) from health billing and cancer registry data. The indicators will include measures relevant to screening, treatment, and follow-up, and will be designed for use in monitoring and evaluating cancer early detection at the state level. Department of Defense/Hollings Cancer Center. Total Direct Costs: \$80,000. 06/01/2000-5/30/2001.

Core Investigator. : Clinical Trials Network: South-Eastern Node. To develop an infrastructure for drug abuse treatment research through a partnership of the MUSC and a network of community treatment programs (CTPs) in the South-Eastern United States in order to (1) conduct clinical trials in a number of areas, including pharmacologic, behavioral, combined pharmacologic/behavioral practice, health services and dissemination research and (2) work collaborative with other Nodes in the NIDA Clinical Trials Network. B. In collaboration with the Steering Committee of the Clinical Trials Network and NIDA, to develop and organizing framework for the Network, including policies on protocol development and review, publications and dissemination, quality control and data management, selection of assessment batteries and outcome measures, treatment development and therapist training, and clinical care. Dr. Simpson is part of the Health Services Research Core, and will provide support for the HSR design and analysis components, with special emphasis on outcomes measurement and economic studies. National Institute on Drug Abuse. Total Direct Cost: \$12.2 million. Start Date: 9/30/2000 End Date: 8/31/2005

Investigator. Veterans Evidence-Based Research Dissemination Implementation Center (VERDICT). Provide consultation on the design of health economics and health services research studies. VA Centers of Excellence Program. San Antonio TX and Charleston SC. 10/1/99-9/30/2003

Principal Investigator. Pharmaco-economics of ABT 378/r for US Patients, and Adaptation of the US model to Brazil, Canada, France, Germany, Italy, the Netherlands, and Spain. Develop an estimating model that uses Abbott clinical trial data from FDA submission, UK, Dutch, and US archival data from an AIDS patient repository at Oxford University (U.K.) and archival/or prospectively collected economic data from each country to estimate differences in survival and cost of care for patients treated with ABT 378 vs currently available drugs. Abbott Laboratories, Therapeutics Division. Total direct cost \$168,000. 11/1/99-12/31/2000.

Principal Investigator. Economics of Pletal vs. Trental for Intermittent Claudication. Modeled improvement in outcomes and costs for patients with intermittent claudication: a comparison of Trental and Pletal based on updating a published model, meta analysis of clinical trial results and archival data analysis. Pharmacia & Upjohn.

Project Director. Cost Functions for Billing Data. Development of methods to use archival data from medical care billing and other repository systems to "fingerprint" institutions' practice patterns and resource use to allow pattern recognition of adherence to guideline for clinical information systems. Chiron Informatics (**US patent received**).

Project Director. Cancer Disease Models. Development of a system of models (based on archival data) to estimate disease incidence, prevalence and lifetime cost of care for patients with lung- bladder- hepatic-cancer, hemophilia, diabetes, osteoporosis, HIV-disease, heart disease and other complex chronic conditions. These models are used to assess research investment opportunities for developments of biotechnology product lines. Nucleic Acid Diagnostics and Therapeutics Divisions, Chiron.

Principal Investigator. Cost of Illness for Patients with AIDS and Other Severe Chronic Conditions. Glaxo Wellcome, Research Triangle Park, NC. Using archival data from multiple sources to estimate disease and cost burden of complex chronic conditions.

Principal Investigator: Pediatric Allergy Learning Study: Quality of life and Economic Component (Protocol 96-219). ACER- Schering Plough.

Investigator. Economic Model for Parkinson's Disease. Research Triangle Institute, NC.

Principal Investigator. Methodological Support for the Development of Guidelines for Management of Autonomic Dysreflexia. Paralyzed Veterans of America, Washington DC.

Principal Investigator. Multinational Trial of Protease Inhibitor AB247 in End-stage AIDS- Economic Component. Abbott Laboratories, Chicago IL.

Principal Investigator. Outcomes, Cost of Illness and Reimbursement Patterns for Septic Shock Patients. Bayer Corporation, West Haven CT.

Principal Investigator. Model Estimates of Costs and Consequences of Combination Therapies with Antiviral Drugs. Roche Laboratories, Nutley NJ.

Principal Investigator. Methodological Support to the Expert Panel on Guidelines for Management of Deep Vein Thrombosis in Paralyzed Individuals. Paralyzed Veterans of America, Washington DC.

Principal Investigator. Model Estimates of Combination Therapy with Antiviral Drugs in Five European Countries, Australia and Canada. Hoffman-La Roche, Basel Switzerland.

Principal Investigator. Case-study Series of Practice Variations and Cost of Therapy for HIV-Infected Patients with Idiopathic Thrombocytopenia (ITP). UNIVAX Inc, Rockville MD.

Principal Investigator. Development of a Pharmaco-Economic Decision Support Model for AIDS Program Management. Roche Laboratories, Nutley NJ.

Principal Investigator. Pilot Project to Assess the Cost-Effectiveness of Drug Utilization Evaluation Programs in Veterans Administration Hospitals. Quality Management Institute, Durham, NC.

Principal Investigator. Cost Effectiveness of Rifabutin Prophylaxis in AIDS patients in the United Kingdom. Battelle Medical Technology and Policy Research Center, Washington, DC, 1993-1994.

Principal Investigator (Economic Component). Cost Utility of new antiviral drugs in AIDS patients in the United States. Battelle MEDTAP, Washington DC

Principal Investigator. Economic analysis to support Consensus Panels on 1) Excessive Use of Ultrasound Technology in Normal Deliveries; and 2) Use of Antenatal Steroids in premature deliveries. National Institute of Child Health and Human Development. N.I.H. Bethesda, M.D.

Principal Investigator (Economic component). "The effect of tiludronate for the treatment of vertebral fractures in post-menopausal women. Battelle MEDTAP, Washington DC, 1993-1997.

Co-principal Investigator. The effect of rural hospital closure on cost and outcomes for Medicare beneficiaries. Agency for Health Care Policy and Research. Grant # 1R01-HS07029-01A1. January 1993-June 1995.

Principal Investigator. "A cost effectiveness study of antiviral treatment with zalcitabine in combination with zidovudine for AIDS patients with CD4 counts < 300 per mm<sup>3</sup>: development of a base model and its adaptation to Switzerland, Germany, France, United Kingdom and Italy." Battelle Medical Technology and Policy Research Center. Washington DC. 1992-1993.

Principal Investigator. "Cost utility analysis of rifabutin for the prevention of Mycobacterium Avium Complex (MAC) disease in AIDS patients." Battelle Medical Technology and Policy Research Center. Washington DC., 1992-1993.

Principal Investigator. "Development of a strategic investment model to forecast the cost effectiveness of new pharmaceutical compounds prior to the institution of clinical trials."Battelle Medical Technology and Policy Research Center, Washington DC., January-September 1992.

Economist. "The cost of tuberculosis in the United States in 1992. Centers for Disease Control, Atlanta GA." Battelle Medical Technology and Policy Research Center. Washington DC.

Principal Investigator. The development of a conceptual model to estimate the interaction between the technical and clinical production functions of the use of bed-side blood analysers in cardiac intensive care patients. Battelle Medical Technology and Policy Research Center. Washington DC.

Principal Investigator. "Development of a Model to Predict the Impact of Investments in Childhood Vaccination Research on Medical Costs and Outcomes." Contract # 263-MD-142293, NIAID, National Institutes of Health. 1991-92. Second award given 1992/93.

Co-Principal Investigator. "Effects of Hospital Closures on Medicare Multiple ADM Patients." National Institute of Mental Health. RO 1 Grant. 1991-94.

Awardee. Faculty Fellowship in Health Care Finance. The Robert Wood Johnson Foundation, 1991-1994 (one of six awards given).

Principal Investigator. "Diffusion and Adoption of Total Quality Management in Hospitals. 1991 Health Care Management Research and Teaching Case Study Development Award, American College of Healthcare Executives (one annual recipient).

Health Economist. Economic Aspects of the Measurement of Effectiveness in the Evaluation of Community Programs for Clinical Research on AIDS." Contract. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Investigator. "Evaluation Design for Community Programs for Clinical Research in AIDS." Contract. Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH.

Principal Investigator. "Community Health Center Teaching Case Development Project." Contract. National Primary Care Institute, Washington, DC.

Principal Investigator. "Management Staff Training Contract," North Carolina Division of Mental Health, Mental Retardation and Substance Abuse.

Project Director. "Pilot Program on Strategic Fiscal and Human Resources Management." Contract. National Primary Care Institute, National Association of Community Health Centers.



Principal Investigator. "A Case Study of Rationing in a National Health System: Denmark." Grant. The University of North Carolina Foundation.

Principal Investigator. "Re-evaluation of the Florida REACH Program." Grant. The Robert Wood Johnson Foundation.

Principal Investigator. "Data Based Interventions for Cancer Control." National Cancer Institute Grant to N.C.D.H.S. UNC Sub-Contract. National Cancer Institute Grant to N.C.D.H.S. UNC Sub-Contract. Mapping of questions for using 20 archival data sources in North Carolina to inform State level cancer control planning and monitoring efforts. 1988

Consultant/Research Scientist. "Small Area Analysis Medical Assessment Pilot Project." To perform the analysis and interpretation of results of Medicare billing data for North Carolina to assess small area variations in hospital admission rates, outcomes and costs for inpatient care. Sub-contract with Medical Review of North Carolina (PRO) on grant from Health Care Financing Administration, Health Standards and Quality Bureau Contract #500-88-004.

Technical Consultant. "Final Evaluation of Management Training Program for In-Charge Community Nurses in Kenya." Technical Leader of Ministry of Health and INTRAH Evaluation Team. US-AID.

Project Director. "Data Based Interventions for Cancer Control." National Cancer Institute Grant to N.C.D.H.S. UNC Sub-Contract. Mapping of questions for using 20 archival data sources in North Carolina to inform State level cancer control planning and monitoring efforts. 1988

Updated 1/14/2019